RAPT Therapeutics (NASDAQ:RAPT) Posts Earnings Results, Beats Expectations By $0.07 EPS

RAPT Therapeutics (NASDAQ:RAPT) announced its quarterly earnings results on Thursday. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.07, MarketWatch Earnings reports.

RAPT Therapeutics stock traded up $1.56 on Friday, reaching $24.36. 1,827 shares of the stock were exchanged, compared to its average volume of 121,451. RAPT Therapeutics has a twelve month low of $10.52 and a twelve month high of $51.21. The firm has a fifty day moving average price of $25.66 and a two-hundred day moving average price of $22.91. The stock has a market cap of $535.41 million and a PE ratio of -2.46.

In related news, insider William Ho sold 7,500 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $18.02, for a total value of $135,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wendye Robbins bought 2,600 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were bought at an average price of $26.01 per share, with a total value of $67,626.00. Following the transaction, the director now directly owns 3,550 shares in the company, valued at $92,335.50. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 5,100 shares of company stock valued at $129,081 and have sold 32,388 shares valued at $918,599. 31.00% of the stock is owned by corporate insiders.

RAPT has been the topic of several recent research reports. Wells Fargo & Co lifted their target price on shares of RAPT Therapeutics from $33.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Cantor Fitzgerald lifted their price objective on shares of RAPT Therapeutics from $37.00 to $51.00 and gave the company an “overweight” rating in a research note on Monday, July 27th. BMO Capital Markets upped their price objective on shares of RAPT Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday. HC Wainwright increased their target price on shares of RAPT Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Zacks Investment Research cut RAPT Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $39.86.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases.

See Also: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.